期刊文献+

LC-MS/MS测定替加环素中的基因毒性杂质9-硝基米诺环素 被引量:2

Determination of Potential Genetoxic Impurity 9-Nitrominocycline in Tigecycline by LC-MS/MS
下载PDF
导出
摘要 建立高效液相色谱-质谱联用的方法测定替加环素中遗传毒性杂质9-硝基米诺环素。方法:选用C 18色谱柱(Welch XB-C 18,4.6×50 mm,5μm),以0.1%甲酸(v/v)为流动相:乙腈为流动相,流速为每分钟0.5 mL,进行线性梯度洗脱;质谱条件:采用电喷雾离子源(ESI),多级反应监测(MRM),正离子扫描模式,干燥气温度为300℃,干燥气流速为8 L/min,雾化气压力为35 psi,鞘流气温度为350℃,鞘流气流速为11 L/min,毛细管端电压为3500 V,喷嘴正电压为500 V,喷嘴负电压为1000 V。离子碰撞能为34 V,扫描时间为500 ms,用于定量分析的MRM离子对为m/z→503.2/153.9。该方法在0.0125~0.9580μg·mL^(-1)的范围内线性良好(0.9999),定量限和检出限分别为0.0125和0.0067μg·mL^(-1),方法回收率94.4%~100.8%之间,稳定性较好。本研究所建立的方法快速、灵敏、专属性强,适用于替加环素中基因毒性杂质9-硝基米诺环素的测定。 To establish a LC-MS/MS method for the determination of the residual quantity of potential genetoxic impurity 9-nitrominocycline in tigecycline.The chromatographic conditions were as follows:a Welch ZORBAX XB-C 18(4.6×50 mm,5μm)column using acetonitrile-water(containing 0.1%formic acid)as the mobile phase in gradient elution.The flow rate was 0.5 mL·min-1.The mass spectrometry conditions were as follows:electrospray ionization source(ESI),multistage reaction monitoring(MRM),positive ion scanning mode,ion spray voltage of 3500 V,ion source temperature of 300℃,Sheath Gas Temp of 350℃,Sheath Gas Flow of 11 L/min,ion collision energy of 34 V and scan time of 500 ms.The MRM ion pair for quantitative analysis was m/z→503.2/153.9.The linear range of 9-nitrominocycline was 0.0125~0.9580μg·mL^(-1)(r=0.9999).The limit of detection was 0.0067μg·mL^(-1) and the limit of quantitation was 0.0125μg·mL^(-1).The average recovery was 94.4%~100.8%.The method is simple,rapid and accurate,and can be used for the quality control of 9-nitrominocycline in tigecycline.
作者 易芬芬 邵婷婷 徐慧娟 Yi Fenfen;Shao Tingting;Xui Huijuan(Hanhui-Pharma,Shanghai 200032,China)
出处 《山东化工》 CAS 2021年第19期126-128,131,共4页 Shandong Chemical Industry
关键词 替加环素 LC-MS/MS 基因毒性杂质 9-硝基米诺环素 tigecycline LC-MS/MS 9-nitrominocycline potential genetoxic impurity
  • 相关文献

参考文献2

二级参考文献8

  • 1Postier RG, Green SL, Klein SR, et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin- structure infections in hospitalized patients. Clin Ther, 2004, 26:704-714. 被引量:1
  • 2Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis, 2005,9.251-261. 被引量:1
  • 3Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis, 2008, 4: 50-55. 被引量:1
  • 4Vasilev K, Reshedko G, Orasan R, et al. A Phase 3, open- label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother, 2005, 62 29-40. 被引量:1
  • 5孙桂凤,陈頔,孙钊.新一代抗菌药物替加环素的研究进展[J].药品评价,2014,11(12):21-23. 被引量:27
  • 6钟雪,陈东科,许宏涛,程刚,胡欣.替加环素研究新进展[J].中国抗生素杂志,2015,40(11):870-875. 被引量:29
  • 7吕鹏,樊晖晖,陈传涛,王运红,张玉,黄怡菲.替加环素在儿童多重耐药菌感染中的研究进展[J].中南药学,2020,18(7):1194-1198. 被引量:3
  • 8王亮亮,王倩倩,周博伦,贾艺鑫,吴华,苑丽,胡功政,贺丹丹.替加环素耐药机制研究进展[J].中国畜牧兽医,2020,47(9):3022-3029. 被引量:7

共引文献2

同被引文献33

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部